Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial

Wai Tong Chien, Jolene H C Mui, Eric F C Cheung, Richard Gray, Wai Tong Chien, Jolene H C Mui, Eric F C Cheung, Richard Gray

Abstract

Background: Non-adherence to antipsychotic medication is commonly found in schizophrenia and other psychotic disorders, thus forming a major obstacle to long-term maintenance treatment and contributing to high relapse rates. With limited evidence on the success of interventions in enhancing medication adherence, this controlled trial was designed to test and evaluate the effectiveness of an adherence therapy (AT) for outpatients with schizophrenia spectrum disorders, based on a motivational interviewing approach over a six-month follow-up period.

Methods: A single-blind, randomized controlled trial with a repeated-measures, two parallel groups design was conducted in a random sample of 114 participants with schizophrenia spectrum disorders in one community psychiatric nursing service. After pre-test, the participants were randomly assigned to either an eight-session course of AT plus usual care or usual psychiatric care (n = 57 per group). The main outcomes, including medication adherence, symptom severity, insight into treatment, hospitalization rate, and functioning, were measured at baseline and immediately and six months post-intervention.

Results: A total of 110 participants completed this trial and thus the attrition rate was 3.5%. Results of repeated-measures analysis of variance followed by Helmert's contrasts test indicated that the AT participants reported significantly greater improvements in their insight into illness and/or treatment, psychosocial functioning, symptom severity, number of re-hospitalizations, and medication adherence (F = 5.01 to 7.45, P = 0.007 to 0.030) over six months follow-up, when compared with usual care.

Conclusions: Motivational interviewing-based AT for people with schizophrenia can be effective to reduce symptom severity and re-hospitalizations, and improve medication adherence, functioning, and insight into illness and/or treatment over a medium term (six months) period of follow-up. Further study on the effects of AT in people with psychotic disorders in terms of diverse sociodemographic and illness characteristics, and a longer term (for example, over 12 months) follow-up period is recommended.

Trial registration: The trial was registered at Clinicaltrials.gov (identifier: NCT01780116) on 6 July 2014.

Figures

Fig. 1
Fig. 1
A flow diagram of the procedure of this clinical trial. After confirming eligibility and written consent, 114 patients with schizophrenia spectrum disorders were randomly selected from a patient list and randomly assigned into one of the two study arms (motivational interviewing-based adherence therapy or treatment as usual) after completing the baseline measurements. Fifty-four participants in the adherence therapy and 56 in the treatment-as-usual group completed one to three post-tests over a six-month follow-up period, and finally included in the data analyses. Only four participants dropped out during the study period. AT, Adherence Therapy; CPNS, Community Psychiatric Nursing Service; ITAQ, Insight and Treatment Attitude Questionnaire; PANSS, Positive and Negative Syndrome Scale; SLOF, Specific Level of Functioning Scale; TAU, Treatment as usual

References

    1. Cheng L-Y, Chan S. Psychoeducation program for Chinese family carers of members with schizophrenia. West J Nurs Res. 2005;27:583–599. doi: 10.1177/0193945905275938.
    1. Naber D, Karow A, Lambert M. Subjective well-being under neuroleptic treatment and its relevance or compliance. Acta Psychiatr Scand. 2005;111:29–34. doi: 10.1111/j.1600-0447.2005.00542.x.
    1. McIntosh AM, Conlon L, Lawrie SM, Stanfield AC. Compliance therapy for schizophrenia. Cochrane Database Syst Rev. 2006;3
    1. Jaeger S, Pfiffner C, Weiser P, Kilian R, Becker T, Längle G, et al. Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study. Psychiatry Res. 2012;200:83–88. doi: 10.1016/j.psychres.2012.03.033.
    1. Gray R, Wykes T, Gournay K. From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. J Psychiatr Ment Health Nurs. 2002;9:277–284. doi: 10.1046/j.1365-2850.2002.00474.x.
    1. Yamada K, Watanabe K, Nemoto N, Fujita H, Chikaraishi C, Yamauchi K, et al. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res. 2006;141:61–69. doi: 10.1016/j.psychres.2004.07.014.
    1. Hui CL, Chen EY, Kan C, Yip K, Law C, Chiu CP. Antipsychotic adherence among out-patients with schizophrenia in Hong Kong. Keio J Med. 2006;55:9–14. doi: 10.2302/kjm.55.9.
    1. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy: 18-month follow-up. Br J Psychiatry. 1998;172:413–419. doi: 10.1192/bjp.172.5.413.
    1. Chien WT, Yip ALK. Current approaches to treatments for schizophrenia spectrum disorders, Part I: an overview and medical treatments. Neuropsychiatr Dis Treat. 2013;9:1311–1332. doi: 10.2147/NDT.S37485.
    1. Maayan N, Quraishi SN, David A, Jayaswai A, Eisenbruch M, Rathbone J, et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015;2
    1. Gray R, White J, Schultz M, Abderhalden C. Enhancing medication adherence in people with schizophrenia: an international programme of research. Int J Ment Health Nurs. 2010;19:36–44. doi: 10.1111/j.1447-0349.2009.00649.x.
    1. Schulz M, Gray R, Spiekermann A, Abderhalden C, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: a multi-centre randomised controlled trial. Schizophr Res. 2013;146:59–63. doi: 10.1016/j.schres.2013.01.028.
    1. Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, et al. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2010;197:448–455. doi: 10.1192/bjp.bp.110.077289.
    1. Robinson DG. Medication adherence and relapse in recent-onset psychosis. Am J Psychiatry. 2011;168:240–242. doi: 10.1176/appi.ajp.2010.10121736.
    1. National Institute of Health and Care Excellence . Psychosis and schizophrenia in adults: treatment and management of schizophrenia. NICE guidelines CG178. London, UK: NICE; 2014.
    1. Gray R, Leese M, Bindman J, Becker T, Burti L, David A, et al. Adherence therapy for people with schizophrenia: European multicentre randomized controlled trial. Br J Psychiatry. 2006;189:508–514. doi: 10.1192/bjp.bp.105.019489.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMJ. 2010;340:698–702. doi: 10.1136/bmj.c332.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) 5. Washington, DC: APA; 2000.
    1. Chien WT, Chan SW, Thompson RD. Effects of mutual support group for Chinese families of people with schizophrenia: 18-month follow-up. Br J Psychiatry. 2006;189:41–49. doi: 10.1192/bjp.bp.105.008375.
    1. Cunningham JB, McCrum-Gardner E. Power, effect and sample size using GPower: practical issues for researchers and members of research ethics committees. Evid Based Midwifery. 2007;5:132–136.
    1. Chien WT, Leung SF. A controlled trial of a needs-based, nurse-led psycho-education program for Chinese patients with first-onset mental disorders: 6-month follow-up. Int J Nurs Practice. 2013;19:s3–s13. doi: 10.1111/ijn.12015.
    1. Chien WT, Yeung FKK, Chan AHL. Perceived stigma of patients with severe mental illness in Hong Kong: relationships with patients’ psychosocial conditions and attitudes for family caregivers and health professionals. Adm Policy Ment Health. 2014;41:237–251. doi: 10.1007/s10488-012-0463-3.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261.
    1. Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D. The positive and negative syndrome scale and brief psychiatric rating scale: reliability, comparability, and predictive validity. J Nerv Ment Dis. 1992;180:723–728. doi: 10.1097/00005053-199211000-00007.
    1. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106:286–290. doi: 10.1034/j.1600-0447.2002.02437.x.
    1. McEvoy JP, Apperson LG, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, et al. Insight in schizophrenia: its relation to acute psychopathology. J Nerv Ment Dis. 1989;177:43–47. doi: 10.1097/00005053-198901000-00007.
    1. Chien WT, Thompson DR. Effects of a mindfulness-based psycho-education programme for Chinese patients with schizophrenia: two-year follow-up. Br J Psychiatry. 2014;205:52–59. doi: 10.1192/bjp.bp.113.134635.
    1. Schneider LC, Struening EL. SLOF: a behavioural rating scale for assessing the mentally ill. Soc Work Res Abstr. 1983;19:9–21. doi: 10.1093/swra/19.3.9.
    1. Chien WT, Chan CWS. One-year follow-up of a multiple-family-group intervention for Chinese families of patients with schizophrenia. Psychiatr Serv. 2004;55:1276–1284. doi: 10.1176/appi.ps.55.11.1276.
    1. Chien WT, Chan S. Further validation of the Chinese version of the level of expressed emotion scale for research and clinical use. Int J Nurs Stud. 2010;47:190–204. doi: 10.1016/j.ijnurstu.2009.05.019.
    1. Tabachnick BG, Fidell LS. Using multivariate analysis. 4. Old Tappan, New Jersey: Allyn & Bacon; 2001.
    1. Stevens J. Applied multivariate statistics for the social sciences. 4. Mahwah, New Jersey: Psychology Press; 2002.
    1. O’Donnell M, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, et al. Compliance therapy: a randomized controlled trial in schizophrenia. BMJ. 2003;327:834. doi: 10.1136/bmj.327.7419.834.
    1. Maneesakorn S, Robson D, Gournay K, Gray R. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs. 2007;16:1302–1312. doi: 10.1111/j.1365-2702.2007.01786.x.
    1. Levensky ER, Forcehimes A, O’Donohue WT, Beitz K. Motivational interviewing: an evidence-based approach to counseling helps patients follow treatment recommendations. Am J Nurs. 2007;107:50–58. doi: 10.1097/01.NAJ.0000292202.06571.24.
    1. Haynes RB, McDonald H, Grag AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2
    1. Yang H. Strategic analysis of clinical trial outsourcing to China [dissertation] British Columbia: Simon Fraser University; 2008.
    1. Hegedüs A, Kozel B. Does adherence therapy improve medication adherence among patients with schizophrenia? A systematic review. Int J Ment Health Nurs. 2014;23:490–497. doi: 10.1111/inm.12089.
    1. Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000;102:203–210. doi: 10.1034/j.1600-0447.2000.102003203.x.
    1. Dawn V, Weiden P, Sajatovic M, Scott J, Carpenter D, Ross R, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from expert consensus guidelines. J Psychiatr Practice. 2010;16:306–324. doi: 10.1097/01.pra.0000388626.98662.a0.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera